• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

New gel combats itching, pain from certain wounds

Article

Petaluma, Calif. - Medical technology company Oculus Innovative Sciences is bringing Microcyn Dermatology HydroGel to the U.S. market, Business Wire reports.

Petaluma, Calif. - Medical technology company Oculus Innovative Sciences is bringing Microcyn Dermatology HydroGel to the U.S. market, Business Wire reports.

Oculus, of Petaluma, Calif., recently announced that it had received Food and Drug Administration (FDA) clearance for the product. The gel, to be used by patients under the supervision of a healthcare professional, is intended for management of wounds including itch and pain relief associated with dermal irritation, sores, injuries and ulcers of dermal tissue.

According to Business Wire, the company is preparing for six additional FDA regulatory clearances for multiple indications including oral, allergy and expanded dermatology claims.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.